Novel therapeutic targets for ARID1A mutant ovarian clear cell carcinoma (OCCC)

被引：0
|
作者：
Miller, R. E. [1 ]
Bajrami, I. [1 ]
Brough, R. [1 ]
Konde, A. [1 ]
Campbell, J. [1 ]
Rafiq, R. [1 ]
Ashworth, A. [1 ]
Lord, C. J. [1 ]
机构：
[1] Inst Canc Res, London SW3 6JB, England
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70444-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
318
引用
收藏
页码：103 / 104
页数：2
相关论文
共 50 条
  • [1] ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies
    Caumanns, Joseph J.
    Wisman, G. Bea A.
    Berns, Katrien
    van der Zee, Ate G. J.
    de Jong, Steven
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2018, 1870 (02): : 176 - 184
  • [2] Identification of novel biomarkers of response to ATR inhibitors in ARID1A mutant ovarian clear cell carcinoma
    Stewart, J. R.
    Baxter, J.
    Zatreanu, D.
    Brough, R.
    Song, F.
    Konde, A.
    Krastev, D.
    Alexander, J.
    Natrajan, R.
    Pettitt, S.
    Banerjee, S.
    Lord, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S383 - S384
  • [3] ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component
    Nishikimi, Kyoko
    Kiyokawa, Takako
    Tate, Shinichi
    Iwamoto, Masami
    Shozu, Makio
    HISTOPATHOLOGY, 2015, 67 (06) : 866 - 871
  • [4] Clinicopathological Significance of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma
    Maeda, D.
    Mao, T-L
    Fukayama, M.
    Wang, T-L
    Shih, I-M
    MODERN PATHOLOGY, 2011, 24 : 259A - 259A
  • [5] HDAC6 AS A THERAPEUTIC TARGET FOR OVARIAN CLEAR CELL CARCINOMA, IN ASSOCIATION WITH ARID1A LOSS
    Yano, M.
    Yasuda, M.
    Miyazawa, M.
    Miwa, M.
    Hasegawa, K.
    Narahara, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 874 - 874
  • [6] Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma
    Maeda, Daichi
    Mao, Tsui-Lien
    Fukayama, Masashi
    Nakagawa, Shunsuke
    Yano, Tetsu
    Taketani, Yuji
    Shih, Ie-Ming
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2010, 11 (12): : 5121 - 5129
  • [7] Clinicopathological Significance of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma.
    Maeda, D.
    Mao, T-L
    Fukayama, M.
    Wang, T-L
    Shih, I-M
    LABORATORY INVESTIGATION, 2011, 91 : 259A - 259A
  • [8] The role of chromatin remodeler protein ARID1a in ovarian clear cell carcinoma
    Lakshminarasimhan, Ranjani
    Andreu-Vieyra, Claudia
    Lawrenson, Kate
    Gayther, Simon A.
    Jones, Peter A.
    Liang, Gangning
    CANCER RESEARCH, 2016, 76
  • [9] ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma
    Sato, Emi
    Nakayama, Kentaro
    Razia, Sultana
    Nakamura, Kohei
    Ishikawa, Masako
    Minamoto, Toshiko
    Ishibashi, Tomoka
    Yamashita, Hitomi
    Iida, Kouji
    Kyo, Satoru
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (06):
  • [10] Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression
    Choi, Jae Yoon
    Han, Hyun Ho
    Kim, Young Tae
    Lee, Joo Hyun
    Kim, Baek Gil
    Kang, Suki
    Cho, Nam Hoon
    YONSEI MEDICAL JOURNAL, 2017, 58 (01) : 59 - 66
12345